$YTENQ
YIELD10 BIOSCIENCE, INC.

2024 Q3 Form 10-Q Financial Statement

#000112170224000065 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $450.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.004M
YoY Change 20.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.004M
YoY Change 20.0%
Operating Profit -$3.203M
YoY Change -12.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$35.00K
YoY Change 150.0%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$3.238M
YoY Change -12.03%
Net Earnings / Revenue -719.56%
Basic Earnings Per Share -$5.04
Diluted Earnings Per Share -$5.04
COMMON SHARES
Basic Shares Outstanding 657.2K shares 642.5K shares
Diluted Shares Outstanding 642.4K shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $733.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.204M
YoY Change -60.2%
LONG-TERM ASSETS
Property, Plant & Equipment $432.0K
YoY Change -34.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K
YoY Change -65.67%
Total Long-Term Assets $1.764M
YoY Change -38.0%
TOTAL ASSETS
Total Short-Term Assets $1.204M
Total Long-Term Assets $1.764M
Total Assets $2.968M
YoY Change -49.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.369M
YoY Change 407.28%
Accrued Expenses $1.828M
YoY Change 32.95%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.669M
YoY Change 210.49%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.669M
Total Long-Term Liabilities
Total Liabilities $9.206M
YoY Change 74.26%
SHAREHOLDERS EQUITY
Retained Earnings -$419.9M
YoY Change 3.12%
Common Stock $413.9M
YoY Change 1.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.238M
YoY Change
Total Liabilities & Shareholders Equity $2.968M
YoY Change -49.44%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.238M
YoY Change -12.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
450000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2004000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
3653000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
3667000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3203000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3667000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-33.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-33.38
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
223603 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
223603 shares
CY2024Q2 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1649000 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
YIELD10 BIOSCIENCE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3158289
dei Entity Address Address Line1
EntityAddressAddressLine1
19 Presidential Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Woburn
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01801
dei City Area Code
CityAreaCode
617
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
501357 shares
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
647000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
103000 usd
CY2024Q2 yten Accrued Lease Cost
AccruedLeaseCost
29000 usd
CY2023Q4 yten Accrued Lease Cost
AccruedLeaseCost
27000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
212000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
452000 usd
CY2024Q2 yten Accrued Field Trials And Related Expenses Current
AccruedFieldTrialsAndRelatedExpensesCurrent
252000 usd
CY2023Q4 yten Accrued Field Trials And Related Expenses Current
AccruedFieldTrialsAndRelatedExpensesCurrent
1032000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
10300 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001121702
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1670000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3378000 usd
dei Local Phone Number
LocalPhoneNumber
583-1700
CY2023Q4 us-gaap Liabilities
Liabilities
6390000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
642497 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
411929000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-265000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-414152000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2483000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3907000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5710000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7463000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0416666666666667
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0416666666666667
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0416666666666667
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
657160 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
733000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1068000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
471000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1204000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1400000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
12000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
432000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
548000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1297000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1653000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 usd
CY2024Q2 us-gaap Assets
Assets
2968000 usd
CY2023Q4 us-gaap Assets
Assets
3907000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2369000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1202000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1828000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2010000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1800000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
676000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
669000 usd
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
996000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
984000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7669000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4865000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1087000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1525000 usd
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
450000 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2024Q2 us-gaap Liabilities
Liabilities
9206000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
642497 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
501357 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413880000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-262000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419862000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6238000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2968000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
750000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60000 usd
CY2023Q2 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1997000 usd
yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
3015000 usd
yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
4159000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3368000 usd
us-gaap Costs And Expenses
CostsAndExpenses
6393000 usd
us-gaap Costs And Expenses
CostsAndExpenses
7527000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5643000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7467000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-67000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-67000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3238000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3681000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.04
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.42
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.84
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
642444 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
642444 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
238716 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
238716 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
580489 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
580489 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3238000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3681000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5710000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7463000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-12000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-16000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3238000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3693000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5707000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7478000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5710000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7463000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145000 usd
yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
26000 usd
yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
63000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
746000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
830000 usd
yten Noncash Lease Expense Income
NoncashLeaseExpenseIncome
250000 usd
yten Noncash Lease Expense Income
NoncashLeaseExpenseIncome
110000 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-30000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
209000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
48000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1162000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
331000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
207000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
436000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2250000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
yten Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-325000 usd
yten Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-180000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1477000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5746000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1991000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1964000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1964000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1174000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
yten Payments Of Financed Insurance Premiums
PaymentsOfFinancedInsurancePremiums
289000 usd
yten Payments Of Financed Insurance Premiums
PaymentsOfFinancedInsurancePremiums
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2717000 usd
yten Proceeds From Sale Of Common Stock At The Market Offering
ProceedsFromSaleOfCommonStockAtTheMarketOffering
0 usd
yten Proceeds From Sale Of Common Stock At The Market Offering
ProceedsFromSaleOfCommonStockAtTheMarketOffering
103000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
41000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
885000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3779000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-587000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1332000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2620000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
745000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2600000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
100000 usd
yten Finance Of Insurance Premiums By Installment
FinanceOfInsurancePremiumsByInstallment
389000 usd
yten Finance Of Insurance Premiums By Installment
FinanceOfInsurancePremiumsByInstallment
0 usd
yten Right Of Use Assets Written Off Due To Lease Termination
RightOfUseAssetsWrittenOffDueToLeaseTermination
106000 usd
yten Right Of Use Assets Written Off Due To Lease Termination
RightOfUseAssetsWrittenOffDueToLeaseTermination
0 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3313000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
343000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
7000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3238000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6238000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1143000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
26000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3681000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
587000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2483000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
718000 usd
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
32000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
28000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5710000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6238000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4400000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
805000 usd
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
56000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
41000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7463000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
587000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
733000 usd
CY2024Q1 yten License Agreement Term
LicenseAgreementTerm
P3Y
CY2024Q1 us-gaap Payment For Management Fee
PaymentForManagementFee
3000000 usd
CY2023Q2 yten Sale Of Stock Maximum Shares
SaleOfStockMaximumShares
38817 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
733000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1068000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
12000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
745000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1332000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
12000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
264000 usd
CY2024Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
12000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of license and grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
yten Consideration Of License Fees To Be Paid
ConsiderationOfLicenseFeesToBePaid
3000000 usd
CY2024Q1 yten License Agreement Term
LicenseAgreementTerm
P3Y
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
2250000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1800000 usd
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
450000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
538554 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
137233 shares
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
100000 usd
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0 usd
CY2024Q2 yten Accrued Ip License Current
AccruedIPLicenseCurrent
267000 usd
CY2023Q4 yten Accrued Ip License Current
AccruedIPLicenseCurrent
5000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
321000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
391000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1828000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2010000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M19D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
25068 shares
CY2022Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2024Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2023Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2021Q1 yten Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Authorized Percent
ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
0.05
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
10416 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
20833 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
29815 shares
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
152000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
150000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
303000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
301000 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
231000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
181000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
406000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
398000 usd
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
162000 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
177000 usd
us-gaap Sublease Income
SubleaseIncome
323000 usd
us-gaap Sublease Income
SubleaseIncome
336000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
221000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
154000 usd
us-gaap Lease Cost
LeaseCost
386000 usd
us-gaap Lease Cost
LeaseCost
363000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0753
CY2016Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
22213 sqft
CY2023Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
12000 usd
CY2024Q2 us-gaap Contractual Obligation
ContractualObligation
75000 usd
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
204000 usd
CY2023Q4 yten Insurance Finance Agreement Premiums Payable Annual Premium
InsuranceFinanceAgreementPremiumsPayableAnnualPremium
549000 usd
CY2023Q4 yten Insurance Finance Agreement Term
InsuranceFinanceAgreementTerm
P8M
CY2023Q4 yten Insurance Finance Agreement Annual Interest Rate
InsuranceFinanceAgreementAnnualInterestRate
0.087
CY2023Q4 yten Insurance Finance Agreement Down Payment
InsuranceFinanceAgreementDownPayment
159000 usd
CY2023Q4 yten Insurance Finance Agreement Premiums Payable Annual Premium Payable After Down Payment
InsuranceFinanceAgreementPremiumsPayableAnnualPremiumPayableAfterDownPayment
390000 usd
CY2023Q4 yten Insurance Finance Agreement Term
InsuranceFinanceAgreementTerm
P8M
CY2024Q2 yten Insurance Finance Agreement Premiums Payable
InsuranceFinanceAgreementPremiumsPayable
100000 usd
CY2024Q1 yten License Agreement Term
LicenseAgreementTerm
P3Y
yten Consideration Of License Fees To Be Paid
ConsiderationOfLicenseFeesToBePaid
3000000 usd
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
2250000 usd
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1800000 usd
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
450000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
450000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
750000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
432000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
548000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
10416 shares
CY2023Q2 yten Sale Of Stock Maximum Shares
SaleOfStockMaximumShares
38817 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1 shares
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
71.52
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
3067 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
28000 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
460953 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
593 shares
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
538554 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
384372 shares
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001121702-24-000065-index-headers.html Edgar Link pending
0001121702-24-000065-index.html Edgar Link pending
0001121702-24-000065.txt Edgar Link pending
0001121702-24-000065-xbrl.zip Edgar Link pending
ex-311x20240630.htm Edgar Link pending
ex-312x20240630.htm Edgar Link pending
ex-321x20240630.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20240630.htm Edgar Link pending
yten-20240630.xsd Edgar Link pending
yten-20240630_def.xml Edgar Link unprocessable
yten-20240630_lab.xml Edgar Link unprocessable
yten-20240630_pre.xml Edgar Link unprocessable
yten-20240630_cal.xml Edgar Link unprocessable
yten-20240630_htm.xml Edgar Link completed